82910 Federal Register / Vol. 88, No. 226 / Monday, November 27, 2023 / Notices 

Countermeasures in accordance with 

this Declaration. 

Liability immunity is afforded to 

manufacturers and distributors without 

regard to whether the countermeasure is 

used by or administered to this 

population; liability immunity is 

afforded to program planners and 

qualified persons when the 

countermeasure is used by or 

administered to this population, or the 

program planner or qualified person 

reasonably could have believed the 

recipient was in this population. 

XI. Geographic Area 

42 U.S.C. 247d–6d(a)(4), 247d– 

6d(b)(2)(D) 

Liability immunity is afforded for the 

administration or use of a Covered 

Countermeasure without geographic 

limitation. 

Liability immunity is afforded to 

manufacturers and distributors without 

regard to whether the countermeasure is 

used by or administered in any 

designated geographic area; liability 

immunity is afforded to program 

planners and qualified persons when 

the countermeasure is used by or 

administered in any designated 

geographic area, or the program planner 

or qualified person reasonably could 

have believed the recipient was in that 

geographic area. 

XII. Effective Time Period 

42 U.S.C. 247d–6d(b)(2)(B) 

Liability immunity for Covered 

Countermeasures through means of 

distribution other than in accordance 

with the public health and medical 

response of the Authority Having 

Jurisdiction and extends through 

December 31, 2028. 

Liability immunity for Covered 

Countermeasures administered and 

used in accordance with the public 

health and medical response of the 

Authority Having Jurisdiction begins 

with a Declaration and lasts through (1) 

the final day the emergency Declaration 

is in effect, or (2) December 31, 2028, 

whichever occurs first. 

XIII. Additional Time Period of 

Coverage 

42 U.S.C. 247d–6d(b)(3)(B) and (C) 

I have determined that an additional 

12 months of liability protection is 

reasonable to allow for the 

manufacturer(s) to arrange for 

disposition of the Covered 

Countermeasure, including return of the 

Covered Countermeasures to the 

manufacturer, and for Covered Persons 

to take such other actions as are 

appropriate to limit the administration 

or use of the Covered Countermeasures. 

Covered Countermeasures obtained 

for the Strategic National Stockpile 

(SNS) during the effective period of this 

Declaration are covered through the date 

of administration or use pursuant to a 

distribution or release from the SNS. 

XIV. Countermeasures Injury 

Compensation Program 

42 U.S.C 247d–6e 

The PREP Act authorizes the 

Countermeasures Injury Compensation 

Program (CICP) to provide benefits to 

certain individuals or estates of 

individuals who sustain a covered 

serious physical injury as the direct 

result of the administration or use of the 

Covered Countermeasures, and benefits 

to certain survivors of individuals who 

die as a direct result of the 

administration or use of the Covered 

Countermeasures. The causal 

connection between the countermeasure 

and the serious physical injury must be 

supported by compelling, reliable, valid, 

medical, and scientific evidence in 

order for the individual to be considered 

for compensation. The CICP is 

administered by the Health Resources 

and Services Administration, within the 

Department of Health and Human 

Services. Information about the CICP is 

available at the toll-free number 1–855– 

266–2427 or http://www.hrsa.gov/cicp/. 

XV. Amendments 

42 U.S.C. 247d–6d(b)(4) 

The December 3, 2014, Declaration 

under the PREP Act for 

Countermeasures Against Ebola Virus 

Disease Vaccines was first published on 

December 10, 2014, and amended and 

republished on December 9, 2015, 

December 12, 2016, and January 31, 

2019. The republished amended 

Declaration for Countermeasures 

Against Ebolavirus and/or Ebola Disease 

and Marburgvirus and/or Marburg 

Disease supersedes the Declaration for 

Countermeasures Against Ebola Virus 

Disease Vaccines. 

The February 27, 2015, Declaration 

under the PREP Act for 

Countermeasures Against Ebola Virus 

Disease Therapeutics was first 

published on April 22, 2015, and 

amended and republished on December 

9, 2015, December 12, 2016, and January 

31, 2019. The republished amended 

Declaration for Countermeasures 

Against Ebolavirus and/or Ebola Disease 

and Marburgvirus and/or Marburg 

Disease supersedes the Declaration for 

Countermeasures Against Ebola Virus 

Disease Therapeutics. 

The November 25, 2020, Declaration 

under the PREP Act for 

Countermeasures Against Marburgvirus 

and/or Marburg Disease was published 

on December 9, 2020. This is the first 

amendment to and republication of the 

Declaration. 

Any further amendments to this 

Declaration will be published in the 

Federal Register, as warranted. 

Authority: 42 U.S.C. 247d–6d. 

Dated: November 21, 2023. 

Xavier Becerra, 

Secretary, Department of Health and Human 

Services. 

[FR Doc. 2023–26075 Filed 11–24–23; 8:45 am] 

BILLING CODE 4150–37–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Amend Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Heart, Lung, 

and Blood Institute Special Emphasis 

Panel T32 Diversity Training Grants, 

December 1, 2023, 11:00 a.m. to 1:00 

p.m., National Institutes of Health, 6705 

Rockledge Drive, Bethesda, MD 20892 

which was published in the Federal 

Register on October 26, 2023, FR 

Document No. 2023–23751, 88 FRN 

73863. 

This notice is being amended to 

change the meeting title to ‘‘The 

National Heart, Lung, and Blood 

Institute Special Emphasis Panel T32 

Member Conflicts SEP.’’ The meeting is 

closed to the public. 

Dated: November 20, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–26020 Filed 11–24–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Customs and Border Protection 

Customs Broker Permit User Fee 

Payment for 2024 and Announcement 

of eCBP Portal Payment Option 

AGENCY: U.S. Customs and Border 

Protection, Department of Homeland 

Security. 

ACTION: General notice. 

SUMMARY: This document provides 

notice to customs brokers that the 

annual user fee that is assessed for each 


khammond on DSKJM1Z7X2PROD with NOTICES